Clik here to view.
Samsung Bioepis First to Receive Positive CHMP Opinion on a Trastuzumab...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on...
View ArticleClik here to view.
瑞士生产出两款用于白内障手术的创新EDOF人工晶体
瑞士纳沙泰尔 (美国商业资讯) — Swiss Advanced Vision公司(SAV-IOL SA)今天宣布上市两种用于白内障手术的新款人工晶体(IOLs) LUCIDIS和EDEN，均采用Instant Focus...
View ArticleClik here to view.
革新的なスイス製の新しい白内障手術用EDOF IOLを2種投入
スイス・ヌーシャテル （ビジネスワイヤ） — Swiss Advanced Vision（SAV-IOL SA）は本日、白内障手術用の新しい眼内レンズ（IOL）として、LUCIDISおよびEDENの2種の市場投入を発表しました。両レンズとも、特許取得済みのInstant Focus...
View ArticleClik here to view.
Cardihab Cardiac Rehab App Spun out of CSIRO eHealth Division
BRISBANE, Australia An Australian solution to dramatically improve recovery from a heart attack today became reality. Cardihab’s technology platform was developed by scientists at the Australian...
View ArticleClik here to view.
Arcus Biosciences Announces Option and License Agreement with Taiho...
HAYWARD, Calif. Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option...
View ArticleClik here to view.
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride...
WOODCLIFF LAKE, N.J. & TOKYO Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) and SymBio Pharmaceuticals Limited (“SymBio”) (Tokyo Stock Exchange/JASDAQ 4582) today announced...
View ArticleClik here to view.
Avita Medical and BARDA Execute a US$24.3m Contract Option
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today...
View ArticleClik here to view.
Evaluate Ltd: Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022...
LONDON & BOSTON & TOKYO & SAN FRANCISCO The “EvaluateMedTech World Preview 2017, Outlook to 2022” report from life science commercial intelligence firm Evaluate Ltd, reveals Medtronic...
View ArticleClik here to view.
SanBio Names Mohammad El-Kalay New Technical Operations SVP
MOUNTAIN VIEW, Calif. SanBio, Inc., a leader in regenerative cell therapies, today announced the appointment of Mohammad El-Kalay, PhD, as Senior Vice President of Technical Operations. In this...
View ArticleClik here to view.
Australian Biotech Leads New Hope for Influenza Control
MELBOURNE, Australia Australian researchers could pave the way for a new approach to influenza control with positive results presented today from preclinical studies demonstrating the effectiveness...
View ArticleClik here to view.
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat...
CAMBRIDGE, Mass. Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of...
View ArticleClik here to view.
MedherantがTEPI Patch®薬物送達システムの評価を目的に日本の大手経皮吸収パッチ企業と契約
英コベントリー （ビジネスワイヤ） — 次世代型経皮薬物送達のリーダー企業Medherantは、貼付剤開発製造の世界最大手の一角を占める日本の経皮吸収パッチ企業（以下「同社」）と契約を締結しました。同社が供給する薬物を送達する当社製TEPI Patch®技術の潜在力の評価を実施することが目的です。...
View ArticleClik here to view.
Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received...
WATERTOWN, Mass. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver...
View ArticleClik here to view.
Vitruvias Therapeutics and Sunny Pharmtech Receive First FDA Generic Drug...
AUBURN, Al. & TAIPEI, Taiwan Sunny Pharmtech Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced...
View ArticleClik here to view.
Clik here to view.
22nd Century与英美烟草之间的限制性许可协议终止
纽约克拉伦斯 (美国商业资讯)–专注于减少烟草中有害成份的植物生物科技公司22nd Century Group, Inc. (NYSE American: XXII)欣然宣布，本公司与英美烟草（投资）有限公司(British American Tobacco (Investments) Limited, “BAT”)在2013年签订的研究许可证和商业选择协议现已到期。BAT不再享有22nd...
View ArticleClik here to view.
Avita Medical Announces Submission of U.S. FDA Premarket Approval (PMA)...
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced...
View ArticleClik here to view.
Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be...
HENDERSON, Nev. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and...
View ArticleClik here to view.
Takeda and SGC Announce a Collaboration Agreement Using Patient Tissue-Based...
OSAKA, Japan & SAN DIEGO & STOCKHOLM Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), Karolinska Institutet (“KI”) and The Structural Genomics Consortium (“SGC”) today announced...
View ArticleClik here to view.
Replicor宣布其针对HBV/HDV合并感染的REP 301研究已在《柳叶刀肠胃病学和肝病学》上发表
蒙特利尔 (美国商业资讯) — Replicor Inc.是一家私营生物制药公司，其目标是治疗慢性乙型肝炎病毒(HBV)以及慢性HBV和丁型肝炎病毒(HDV)合并感染的患者，该公司今天宣布其针对REP 2139和聚乙二醇干扰素α-2a (pegIFN)的活性进行的REP 301研究已在《柳叶刀肠胃病学和肝病学》(The Lancet Gastroenterology &...
View Article